Storia della carriera di Nelson Chau
Precedenti posizioni note di Nelson Chau
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| LOGICBIO THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | 01/09/2017 | 01/05/2021 |
| REGULUS THERAPEUTICS INC. | Direttore Tecnico/Scientifico/R&S | - | - |
| TRANSLATE BIO, INC. | Corporate Officer/Principal | - | - |
Formazione di Nelson Chau
| The Johns Hopkins University School of Medicine | Doctorate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 5 |
Posizioni
| Chief Tech/Sci/R&D Officer | 2 |
| Corporate Officer/Principal | 1 |
| Doctorate Degree | 1 |
Settori
| Health Technology | 4 |
| Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| REGULUS THERAPEUTICS INC. | Health Technology |
| Aziende private | 2 |
|---|---|
LogicBio Therapeutics, Inc.
 LogicBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology LogicBio Therapeutics, Inc. engages in the development of a genome editing technology platform. It focuses on the commercialization of GeneRide, which enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. Its pipeline includes LB-001, LB-301 and LB-401. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Lexington, MA. | Health Technology |
Translate Bio, Inc.
 Translate Bio, Inc. BiotechnologyHealth Technology Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidate, MRT5005 is designed for the treatment of cystic fibrosis. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA. | Health Technology |
- Borsa valori
- Insiders
- Nelson Chau
- Esperienza
